The DOI matches its Crossref record.
Fate of Cerebrospinal Fluid‐Borne Amyloid β‐Peptide: Rapid Clearance into Blood and Appreciable Accumulation by Cerebral Arteries
Abstract
In Alzheimer's disease, the neuritic or senile amyloid plaques in hippocampus and association cortex, the diffuse plaques in brain areas such as the cerebellum and sensorimotor cortex, and the amyloid deposits in the walls of pial and parenchymal blood vessels are mainly composed of amyloid beta-peptides. In the present study, either soluble 40-residue amyloid beta-peptide radiolabeled with 125I (I-sAbeta) or [14C]polyethylene glycol ([14C]PEG, a reference material) was briefly infused into one lateral ventricle of normal rats. By 3.5 min, 30% of the I-sAbeta was cleared from ventricular CSF into blood; another 30% was removed over the next 6.5 min. No [14C]PEG was lost from the CSF-brain system during the first 5 min, and only 20% was cleared by 10 min. Much of the I-sAbeta that reached the subarachnoid space was retained by pial arteries and arterioles. Virtually no I-sAbeta was found in brain. The clearance of amyloid beta-peptides from the CSF-brain system, reported herein for normal rats, may be reduced in Alzheimer's disease, thus contributing to amyloid deposition in cerebral tissue and blood vessels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“because CSF A, which has a high concentration relative to plasma A, is normally cleared into blood (Ghersi-Egea et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Ghersi-Egea et al., 1996
In the citing paper
“The absolute amounts of both tracers in the CSF and plasma were low, however, due to relatively rapid clearance from the CSF in comparison to slow ISF bulk flow (29), and significant systemic body clearance (48), respectively.”
From Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier (2000) · cites this paper as [29]
In the citing paper
“Transport of A b out of the CSF was not associated with significant degradation of peptide in the CSF (29).”
From Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier (2000) · cites this paper as [29]
In the citing paper
“Lower levels of A b 1-40 than inulin in the CSF may suggest active transport of A b from the CSF to the blood, possibly across the choroid plexus or leptomeningeal vessels, as shown previously (29).”
From Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier (2000) · cites this paper as [29]
Citations
Cited by
Sorted by citations
Items 201–215 of 215
Evaluation of Blood-CSF Barrier Transport by Quantitative Real Time Fluorescence Microscopy
Sun, A., & Wang, J. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03251-9 · Cited by 2
Understanding the Liver’s Role in the Clearance of Aβ40
Lockwood, G. P., Hunt, N. J., Kockx, M., Kang, S. W., Couteur, D. G. L., & Cogger, V. C. (2024) · Livers · doi:10.3390/livers4020018 · Cited by 1
N’Go, P. K., Tehoua, L., Ahami, O. T. A., Azzaoui, F.-Z., & Aboussaleh, Y. (2021) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2220 · Cited by 2
Leptin, Insulin and Blood-Brain Barrier Relations in Obesity
Banks, W. A., Nonaka, N., Shioda, S., Nakaoke, R., & Morley, J. E. (2005) · Elsevier eBooks · doi:10.1016/b978-84-8174-892-5.50012-7 · Cited by 1
McGirr, A., Vila-Rodriguez, F., & Cusimano, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-407824-6.00010-0 · Cited by 1
Banks, W. A. (2004) · Elsevier eBooks · doi:10.1016/b978-012639011-7/50012-7 · Cited by 1
Effects of a Peripheral Anti-Aβ Antibody on Plasma and CNS Aβ Clearance
Holtzman, D. M., Bales, K. R., Paul, S. M., & Demattos, R. B. (2003) · Springer eBooks · doi:10.1007/978-3-642-59332-1_8 · Cited by 1
Vascular Transport of Alzheimer’s Amyloid β Peptides and Apolipoproteins
Zloković, B. V., Ghiso, J. A., & Frangione, B. (2000) · Springer eBooks · doi:10.1007/978-94-017-1007-7_20 · Cited by 1
Self-citationArachnoid granulations: Dynamic nature and review.
Ko, A., Abdelmonem, A., & Taheri, M. R. (2024) · Current problems in diagnostic radiology · doi:10.1067/j.cpradiol.2024.12.006
The role of human serum albumin in prevention and treatment of Alzheimer’s disease
Shevelyova, M. P., Deryusheva, E. I., Леонидовна, Н. Е., Валериевич, М. А., & Андреевна, Л. Е. (2023) · Журнал общей биологии · doi:10.31857/s0044459623020069 · Cited by 1
Biochemical signature in Alzheimer’s disease
Nehra, R. (2017) · International Journal of Advanced Biochemistry Research · doi:10.33545/26174693.2017.v1.i2a.86
“Past researches have shown that Aβ infused into the ventricular CSF of rodent is quickly cleared into blood, probably by sub ependymal vessels and the choroid plexuses ([21]).”
BackgroundT-Cell Migration Across the Blood–Brain Barrier in CNS Inflammatory Diseases
Fabry, Z., Reinke, E., & Karman, J. (2005) · doi:10.1201/b14290-10
Analysis of β-Amyloid Peptide Degradation In Vitro.
Cordell, B., & Naidu, A. (2000) · Methods in Molecular Medicine · doi:10.1385/1-59259-195-7:139
Cole (2000) · doi:10.1002/1097-0029(20000815)50:4
Self-citation
Metadata
- Authors
- Ghersi‐Egea, J. ‐., Gorevic, P. D., Ghiso, J., Frangione, B., Patlak, C. S., & Fenstermacher, J. D.
- Affiliations
- Stony Brook University (US)
- NYU Langone Health (US)
- Henry Ford Hospital (US)
- Corresponding author
- Fenstermacher, J. D.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 1996-08
- Volume
- 67
- Issue
- 2
- Pages
- 880-883
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2065410730
- Cited by
- 222
- References
- 0
- Citations by year
- 2025: 3 · 2024: 7 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 3 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 7 · 2015: 9 · 2014: 8 · 2013: 8 · 2012: 7
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- National Institutes of Health (5r01ns026004-05, 5r29ag010593-05)
- National Institute on Aging (AG10593, AG05891)
- National Institute of Neurological Disorders and Stroke (NS-26004)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- amyloid-beta, cerebrospinal fluid, blood-CSF barrier, cerebral arteries, pial arteries, amyloid deposition, Alzheimer's disease, subarachnoid space
- MeSH terms
- Animals, Cerebral Arteries, Humans, Male, Metabolic Clearance Rate, Peptide Fragments, Amyloid beta-Peptides, Rats, Sprague-Dawley, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
